Clinical implications of intratumor heterogeneity: challenges and opportunities
Hebron University · Universitat Autònoma de Barcelona · +7 more institutions
Abstract
In this review, we highlight the role of intratumoral heterogeneity, focusing on the clinical and biological ramifications this phenomenon poses. Intratumoral heterogeneity arises through complex genetic, epigenetic, and protein modifications that drive phenotypic selection in response to environmental pressures. Functionally, heterogeneity provides tumors with significant adaptability. This ranges from mutual beneficial cooperation between cells, which nurture features such as growth and metastasis, to the narrow escape and survival of clonal cell populations that have adapted to thrive under specific conditions such as hypoxia or chemotherapy. These dynamic intercellular interplays are guided by a Darwinian…
Citation impact
- FWCI
- 21.36
- Percentile
- 100%
- References
- 211
Authors
8- SRSantiago Ramón y CajalCorresponding
Hebron University, Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Centro de Investigación Biomédica en Red de Cáncer
- MSMarta Sesé
Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Centro de Investigación Biomédica en Red de Cáncer
- CCClaudia Capdevila
Universitat Autònoma de Barcelona, Columbia University Irving Medical Center, Vall d'Hebron Institut de Recerca
- TATrond Aasen
Universitat Autònoma de Barcelona, Vall d'Hebron Institut de Recerca, Centro de Investigación Biomédica en Red de Cáncer
- LDLeticia De Mattos‐Arruda
Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology
Topics & keywords
- Epigenetics
- Biology
- Genetic heterogeneity
- Tumor heterogeneity
- Phenotype
- Tumor microenvironment
- Metastasis
- Adaptability
- Partnerships for the goals
Funding
- GDGeneralitat de CatalunyaAward: 2017 SGR
- CDCentro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y NanomedicinaAward: CB16/12/00363 CIBERONC
- CDCentro de Investigación Biomédica en Red de CáncerAward: CB16/12/00363
- ADAgència de Gestió d'Ajuts Universitaris i de RecercaAwards: 2017 SGR 1799, 2014 SGR 1131, 2017 SGR
- IDInstituto de Salud Carlos IIIAwards: PI16/, CB16/12/00363, PI14/, PI16/00772, PI17/02247, CPII16/00042, PI14/01320
- EREuropean Regional Development Fund